Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia

1 Jun 2007

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Myeloid Leukemia Treatments
Share to RNA Interference and Gene Delivery

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 17609876
DOI: 10.1007/s10238-007-0125-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemiaPMID 17609876Read ↗

Stable RNA interference (RNAi) as an option for anti-bcr-abl therapySemantic proximity Read ↗

Specific inhibition of bcr-abl gene expression by small interfering RNASemantic proximity Read ↗

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.Semantic proximity Read ↗

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatmentSemantic proximity Read ↗

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571)Semantic proximity Read ↗

Targeting primary human leukaemia cells with RNA interference: Bcr‐Abl targeting inhibits myeloid progenitor self‐renewal in chronic myeloid leukaemia cellsSemantic proximity Read ↗

Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapySemantic proximity Read ↗

Restoration of miR-424 suppresses BCR–ABL activity and sensitizes CML cells to imatinib treatmentSemantic proximity Read ↗

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon αSemantic proximity Read ↗

Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.Semantic proximity Read ↗

Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.Semantic proximity Read ↗

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-CSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.